Chemokine receptors and signaling
Research Guide

Chemokine receptors such as CXCR4 and CCR7 guide breast cancer cells to metastatic sites like lymph nodes and lungs, as demonstrated in "Involvement of chemokine receptors in breast cancer metastasis" (Müller et al., 2001). This directional migration mimics leukocyte trafficking during inflammation. Blocking these receptors inhibits metastasis in preclinical models.

Chemokine signaling recruits inflammatory cells that produce growth factors, proteases, and angiogenic factors supporting tumor progression, per "Inflammation and cancer" (Coussens and Werb, 2002). Chronic inflammation links to malignancy, echoing Virchow's hypothesis in "Inflammation and cancer: back to Virchow?" (Balkwill and Mantovani, 2001). This process involves macrophage activation via chemokines.

The chemokine system activates and polarizes macrophages into pro-tumor M2 or anti-tumor M1 phenotypes, as outlined in "The chemokine system in diverse forms of macrophage activation and polarization" (Mantovani et al., 2004). Tumor-associated macrophages often adopt an M2-like state promoting angiogenesis and immune suppression. Standardized nomenclature appears in "Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines" (Murray et al., 2014).

Chemokines like MCP-1 recruit monocytes to tumor sites, detailed in "Monocyte Chemoattractant Protein-1 (MCP-1): An Overview" (Deshmane et al., 2009). They belong to families based on cysteine motifs and direct selective leukocyte migration. "Chemokines" (Zlotnik and Yoshie, 2000) classifies over 40 human chemokines into CXC, CC, XC, and CX3C subfamilies.

Chemokine receptors on tumor and immune cells are targets for inhibiting metastasis and reprogramming tumor-associated macrophages, as in "Tumor-Associated Macrophages: From Mechanisms to Therapy" (Noy and Pollard, 2014). Antagonists of CXCR4 show preclinical efficacy against breast cancer spread. Inflammation-driven chemokine signaling provides additional intervention points.